Business
Aurinia Pharmaceuticals to Present at Two Upcoming Virtual Healthcare Conferences
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the
About this update from Aurinia Pharmaceuticals Inc
[{"type":"text","content":" VICTORIA, British Columbia--(BUSINESS WIRE)--\nAurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the management team will participate in two upcoming virtual investor conferences and participate in a panel discussion hosted by Dr. Scott Gottlieb, former FDA Commissioner:\n\n\nH.C. Wainwright Virtual BioConnect 2021 Conference. On-demand fireside chat available beginning Monday, January 11, 2021 at 6:00 a.m. EST;\n\n\nScott Gottlieb, M.D. Hosts a Panel Discussion on Clinical Trials with Neil Solomons, M.D., Chief Medical Officer of Aurinia, during the H.C. Wainwright BioConnect 2021 Conference on Monday, January 11, 2021 at 12:00 p.m. EST; and\n\n\nJ.P Morgan 39th Annual Healthcare Conference. Fireside chat to be hosted on Thursday, January 14, 2021 at 4:30 p.m. EST.\n\n\nIn order to listen to the audio webcast, interested parties can register and access the live webcast under “News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available for 30 days on Aurinia’s website.\n\nABOUT AURINIA\n\nAurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company is currently seeking FDA approval of voclosporin for the potential treatment of lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia and its U.S. commercial hub is in Rockville, Maryland. The Company focuses its development efforts globally.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210108005055/en/\n\nInvestor & Corporate Contact:\nGlenn Schulman, PharmD, MPH\nSVP, Corporate Communications & IR\[email protected]\n\nSource: Aurinia Pharmaceuticals Inc.","length":3613,"tagName":"div"}]